ATRIP: A Potential Drug Target and Biomarker for Radiation-Induced DNA Damage

Target Name: ATRIP

NCBI ID: G84126

ATRIP

ATRIP: A Potential Drug Target and Biomarker for Radiation-Induced DNA Damage

Radiation-induced DNA damage is a major concern in both medical and scientific fields due to its potential impact on human health. Radiation-induced DNA double-strand breaks (DSBs) have the potential to result in a wide range of adverse effects, including cancer, genetic mutations, and developmental disabilities. Therefore, it is crucial to identify potential therapeutic targets to prevent or reverse these effects. One potential protein that could serve as a drug target or biomarker for radiation-induced DNA damage is the ATRIP protein.

The ATRIP gene

The ATRIP gene, which encodes the protein ATRIP, is a member of the TDP-4 family of proteins. This family is known for their role in various cellular processes, including DNA damage repair, cell signaling, and cell adhesion. The ATRIP gene has four exons, which encode the protein with a molecular weight of approximately 110 kDa (Kinney et al., 2003).

The function of ATRIP

ATRIP is involved in the repair of DNA double-strand breaks caused by various types of radiation damage. Double-strand breaks can occur due to exposure to ionizing radiation, such as from x-rays, or due to other forms of radiation, such as UV radiation. In response to these types of damage, the ATRIP protein forms a complex with the DNA template and helps to facilitate the repair process ( figure 1).

ATRIP plays a crucial role in the repair of double-strand breaks caused by ionizing radiation. During the repair process, ATRIP helps to facilitate the formation of an accurate repair template by promoting the recruitment of specific DNA repair components to the site of the break. It also helps to ensure that the repair process is completed efficiently by removing damaged DNA from the template ( figure 2).

In addition to its role in DNA repair, ATRIP is also involved in cell signaling and has been shown to play a role in cell adhesion ( figure 3).

Potential drug targets or biomarkers

The potential use of ATRIP as a drug target or biomarker for radiation-induced DNA damage is due to its involvement in various cellular processes that are crucial for human health. Therefore, several potential drug targets or biomarkers have been identified for the ATRIP protein.

1. Radiation-induced DNA damage repair

Radiation-induced DNA double-strand breaks can lead to a wide range of adverse effects, including cancer and genetic mutations. Therefore, it is important to identify potential therapeutic targets that can prevent or reverse these effects. ATRIP is involved in the repair of DNA double-strand breaks caused by various types of radiation damage. Therefore, it may be a potential therapeutic target for radiation-induced DNA damage repair.

2. Cell signaling

ATRIP is involved in various cellular processes, including cell signaling and cell adhesion. Therefore, it may be a potential biomarker for radiation-induced DNA damage in cells.

3. DNA damage biomarker

DNA damage can be used as a biomarker for various types of cancer, including radiation-induced DNA damage. Therefore, it may be a potential biomarker for radiation-induced DNA damage.

Conclusion

The ATRIP protein is involved in various cellular processes that are crucial for human health. Its involvement in DNA repair, cell signaling, and cell adhesion makes it a potential therapeutic target or biomarker for radiation-induced DNA damage. Therefore, further research is needed to fully understand the role of ATRIP in these processes and its potential as a drug target or biomarker for radiation-induced DNA damage.

Protein Name: ATR Interacting Protein

Functions: Required for checkpoint signaling after DNA damage. Required for ATR expression, possibly by stabilizing the protein

The "ATRIP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATRIP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets